53994-85-7

Usage

Uses

Used in Organic Synthesis:
N-Boc-(4'-Chlorophenyl)glycine is used as a building block for the creation of a wide range of chemical substances. Its functional groups, including carboxylic esters and amines, make it a versatile compound in the synthesis of various organic compounds.
Used in Peptide Synthesis:
N-Boc-(4'-Chlorophenyl)glycine is used as a reagent in peptide synthesis. The N-Boc protecting group is essential in preventing unwanted side reactions during the synthesis process, ensuring the formation of the desired peptide sequence.
Used in Pharmaceutical Industry:
N-Boc-(4'-Chlorophenyl)glycine is used as an intermediate in the synthesis of pharmaceutical compounds. Its presence in the synthesis process allows for the creation of complex drug molecules with potential therapeutic applications.
Used in Chemical Research:
N-Boc-(4'-Chlorophenyl)glycine is used as a research tool in the study of chemical reactions and mechanisms. Its unique structure and functional groups provide insights into the behavior of similar compounds and contribute to the understanding of chemical processes.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 6212-33-5 2-(4-Chlorophenyl)glycine 
• 43189-37-3 (R)-2-amino-2-(4-chlorophenyl)acetic acid 
• 124-38-9 carbon dioxide 
• 774225-25-1 N-(tert-butoxycarbonyl)-α-(phenylsulfonyl)-4-chlorobenzylamine 
• 1291065-80-9 C₂₄H₄₂ClNO₂Sn 
• 104-88-1 4-chlorobenzaldehyde 
• 4248-19-5 tert-butyl carbazate 

Downstream Products

• 1097078-87-9 C₂₉H₂₉Cl₄N₃O₃ 
• 1171244-89-5 tert-butyl 1-(4-chlorophenyl)-2-hydrazinyl-2-oxoethylcarbamate 
• 1193334-09-6 tert-butyl 1-(4-chlorophenyl)-2-(ethylamino)-2-oxoethylcarbamate 
• 1193334-10-9 2-amino-2-(4-chlorophenyl)-N-ethylacetamide 
• 1432669-78-7 (R)-ethyl 2-((2S,3R)-2,3-bis(4-chlorophenyl)-5-oxomorpholino)pentanoate 

Relevant academic research and scientific papers

Synthesis ofN-Boc-α-amino Acids from Carbon Dioxide by Electrochemical Carboxylation ofN-Boc-α-aminosulfones

Electrochemical reduction ofN-Boc-α-aminosulfones in DMF using an undivided cell equipped with a Pt plate cathode and an Mg rod anode under atmospheric pressure of bubbling carbon dioxide through the solution under constant current conditions resulted in a reductive C-S bond cleavage with elimination of benzenesulfinate ion generating the corresponding anion species followed by fixation of carbon dioxide to give the correspondingN-Boc-α-amino acids in moderate to good yields.

Extensive investigation of benzylic N-containing substituents on the pyrrolopyrimidine skeleton as Akt inhibitors with potent anticancer activity

Continuous optimization of benzylic substituents on 1-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperazin-1-yl)-2-phenylethan-1-one structure as Akt inhibitors was described in this paper. Particularly, compounds 8 and 14g exhibited high enzymatic potency against all Akt isoforms and antiproliferative effects in mantle cell lymphoma cell lines, as well as favorable cytotoxicities in patient primary cancer cells. Low micromolar doses of both 8 and 14g dose-dependently induced cell apoptosis and G2/M cell cycle arrest, also suppressed the phosphorylation level of Akt downstream targets GSK3β and S6.

Substituted p-chlorophenyl acetylpiperazine-containing compound as well as preparation method and application thereof

The application provides a substituted p-chlorophenyl acetylpiperazine-containing compound as well as a preparation method and application of the substituted p-chlorophenyl acetylpiperazine-containingcompound. The compound has the structure shown in the formula (I), and has better Akt1 inhibitory activity or growth inhibitory activity to MCL cell lines.

CIS-MORPHOLINONE AND OTHER COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER

The present invention provides MDM2 inhibitor compounds of Formula (I), or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

HETEROCYCLIC COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER

The present invention provides MDM2 inhibitor compounds of Formula I or II, or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

Rational design and binding mode duality of MDM2-p53 inhibitors

Structural analysis of both the MDM2-p53 protein-protein interaction and several small molecules bound to MDM2 led to the design and synthesis of tetrasubstituted morpholinone 10, an MDM2 inhibitor with a biochemical IC 50 of 1.0 μM. The cocrystal structure of 10 with MDM2 inspired two independent optimization strategies and resulted in the discovery of morpholinones 16 and 27 possessing distinct binding modes. Both analogues were potent MDM2 inhibitors in biochemical and cellular assays, and morpholinone 27 (IC50 = 0.10 μM) also displayed suitable PK profile for in vivo animal experiments. A pharmacodynamic (PD) experiment in mice implanted with human SJSA-1 tumors showed p21WAF1 mRNA induction (2.7-fold over vehicle) upon oral dosing of 27 at 300 mg/kg.

Synthesis of arylglycine and mandelic acid derivatives through carboxylations of α-amido and α-acetoxy stannanes with carbon dioxide

Incorporation reactions of carbon dioxide (CO2) with N-Boc-α-amido and α-acetoxy stannanes were developed using CsF as a mild tin activator. Monoprotected α-amido stannanes could be used, and the corresponding arylglycine derivatives were obtained in moderate-to-high yields under 1 MPa (10 atm) of CO2 pressure. α-Acetoxy stannanes also underwent carboxylation to afford mandelic acid derivatives in excellent yields under ambient CO2 pressure. Both transformations enabled the synthesis of α-tertiary and α-quaternary carboxylic acid derivatives. In addition, the chirality of (S)-N-tert-butylsulfonyl-α- amido stannanes was transferred with up to 90% inversion of configuration at 100 °C.

GLYCINE DERIVATIVES AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS

The present invention relates to alkaloid aminoester derivatives acting as muscarinic receptor antagonists, processes for their preparation, compositions comprising them and therapeutic uses thereof.

GLYCINE DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF

Alkaloid aminoester derivatives according to formula (I) and (VI) act as muscarinic receptor antagonists.

One-pot synthesis of α-amino acids from imines through CO2 incorporation: An alternative method for strecker synthesis

Itas a gas: A novel one-pot process for the synthesis of α-amino acids from imine equivalents using CO2 gas as a carbon source has been developed. This reaction was made possible by the reagent combination of TMSSnBu3 and CsF (see scheme). Three successive reactions (imine formation, stannylation, and carboxylation) proceeded in the same flask under these conditions to give products in up to 79 % yield. Boc=tert-butoxycarbonyl, TMS=trimethylsilyl.